Erleada
Janssen’s Erleada expanded in Europe to cover metastatic hormone-sensitive prostate cancer
January 29, 2020Research and Development, Sales and Marketing Erleada, Europe, Janssen, pharma
Janssen’s Erleada (apalutamide) has secured expanded authorisation from the European Commission (EC), approving its label to include the treatment of …
FDA expands Janssen’s Erleada label to cover metastatic castration-sensitive prostate cancer
September 19, 2019Sales and Marketing Cancer, Erleada, FDA, Janssen, pharma, prostate cancer
Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the …
Janssen’s Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer
June 3, 2019Research and Development, Sales and Marketing ASCO 2019, Cancer, Erleada, Janssen, prostate cancer
Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new …
Janssen’s Erleada meets primary endpoints in ongoing trial into metastatic castration-sensitive prostate cancer
January 31, 2019Research and Development Cancer, Erleada, Janssen, pharma, prostate cancer
Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been …
J&J’s apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup
February 15, 2018Sales and Marketing Cancer, Erleada, FDA, J&J, JJ, Johsnon & Johnson, apalutamide, pharma, prostate cancer
Johnson & Johnson has announced that its androgen receptor inhibitor apalutamide, now branded as Erleada, has received approval from the …
